Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites.

Bibliographic Details
Title: Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites.
Authors: McPhillie, Martin J., Zhou, Ying, Hickman, Mark R., Gordon, James A., Weber, Christopher R., Li, Qigui, Lee, Patty J., Amporndanai, Kangsa, Johnson, Rachel M., Darby, Heather, Woods, Stuart, Li, Zhu-hong, Priestley, Richard S., Ristroph, Kurt D., Biering, Scott B., El Bissati, Kamal, Hwang, Seungmin, Hakim, Farida Esaa, Dovgin, Sarah M., Lykins, Joseph D.
Source: Frontiers in Cellular & Infection Microbiology; 6/17/2020, Vol. 10, p1-27, 27p
Subject Terms: CYTOCHROME b, TOXOPLASMA gondii, PARASITES, PLASMODIUM falciparum, TOXOPLASMOSIS
Abstract: Apicomplexan infections cause substantial morbidity and mortality, worldwide. New, improved therapies are needed. Herein, we create a next generation anti-apicomplexan lead compound, JAG21, a tetrahydroquinolone, with increased sp3-character to improve parasite selectivity. Relative to other cytochrome b inhibitors, JAG21 has improved solubility and ADMET properties, without need for pro-drug. JAG21 significantly reduces Toxoplasma gondii tachyzoites and encysted bradyzoites in vitro , and in primary and established chronic murine infections. Moreover, JAG21 treatment leads to 100% survival. Further, JAG21 is efficacious against drug-resistant Plasmodium falciparum in vitro. Causal prophylaxis and radical cure are achieved after P. berghei sporozoite infection with oral administration of a single dose (2.5 mg/kg) or 3 days treatment at reduced dose (0.625 mg/kg/day), eliminating parasitemia, and leading to 100% survival. Enzymatic, binding, and co-crystallography/pharmacophore studies demonstrate selectivity for apicomplexan relative to mammalian enzymes. JAG21 has significant promise as a pre-clinical candidate for prevention, treatment, and cure of toxoplasmosis and malaria. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Cellular & Infection Microbiology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:22352988
DOI:10.3389/fcimb.2020.00203
Published in:Frontiers in Cellular & Infection Microbiology
Language:English